LIFECORE BIOMEDICAL, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
LIFECORE BIOMEDICAL, INC. (LFCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 22.95 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 2.55K shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 20.40K shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 147.18K shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-05-25 was 288.54K shares, a 2208.34% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 1.45M shares, a 997.75% increase from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 132.35K shares, a 44.63% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 239.04K shares, a 25.80% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 322.17K shares, a 26.32% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 7 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 2.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 22.95K shares 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 20.40K shares 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | 218.21K shares 10-KT · filed 2026-03-16 | ||||
| 2025-09-30 | 147.18K shares 10-Q · filed 2025-11-06 | ||||
| 2025-05-25 | 288.54K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-07 | 1.18M shares derived: sum of 2 quarters · filed 2025-08-07 | 1.38M shares derived: sum of 3 quarters · filed 2025-08-07 | 1.45M shares 10-K · filed 2025-08-07 | |
| 2025-02-23 | 892.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-03 | 1.09M shares derived: sum of 2 quarters · filed 2025-04-03 | 1.16M shares 10-Q · filed 2025-04-03 | 1.18M shares derived: sum of 4 quarters · filed 2025-04-03 | |
| 2024-11-24 | 197.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-02 | 272.07K shares 10-Q · filed 2025-01-02 | 284.57K shares derived: sum of 3 quarters · filed 2025-01-02 | 284.57K shares derived: sum of 4 quarters · filed 2025-01-02 | |
| 2024-08-25 | 75.00K shares 10-Q · filed 2024-10-04 | 87.50K shares derived: sum of 2 quarters · filed 2024-10-04 | 87.50K shares derived: sum of 3 quarters · filed 2024-10-04 | 87.50K shares derived: sum of 4 quarters · filed 2024-10-04 | |
| 2024-05-26 | 12.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | 12.50K shares derived: sum of 2 quarters · filed 2024-08-26 | 12.50K shares derived: sum of 3 quarters · filed 2024-08-26 | 132.35K shares 10-K · filed 2024-08-26 | |
| 2024-02-25 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | 0.00 shares derived: sum of 2 quarters · filed 2024-08-09 | 119.85K shares 10-Q · filed 2024-08-09 | ||
| 2023-11-26 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 119.85K shares 10-Q · filed 2024-08-09 | |||
| 2023-08-27 | 119.85K shares 10-Q · filed 2024-08-09 | ||||
| 2023-05-28 | 239.04K shares 10-K · filed 2024-03-20 | ||||
| 2022-05-29 | 322.17K shares 10-K · filed 2024-03-20 | ||||
| 2021-05-30 | 437.23K shares 10-K · filed 2024-03-20 | ||||
| 2020-05-31 | 499.60K shares 10-K/A · filed 2023-03-16 | ||||
| 2019-05-26 | 135.00K shares 10-K · filed 2021-07-29 | ||||
| 2018-05-27 | 61.54K shares 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |